Number of the records: 1
Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system
- 1.
SYSNO ASEP 0103842 Document Type J - Journal Article R&D Document Type Journal Article Subsidiary J Ostatní články Title Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system Title Antidiabetické mechanizmy inhibitoru angiotensin konvertujícího enzymu a angiotensin II antagonistu: nad rámec systému renin-angiotensin Author(s) Kurtz, T. W. (US)
Pravenec, Michal (FGU-C) RID, ORCIDSource Title Journal of Hypertension. - : Lippincott Williams & Wilkins - ISSN 0263-6352
Roč. 22, č. 12 (2004), s. 2253-2261Number of pages 9 s. Language eng - English Country US - United States Keywords angiotensin II receptors ; metabolic syndrome ; peroxisome proliferator activated receptors Subject RIV EB - Genetics ; Molecular Biology R&D Projects GA301/03/0751 GA ČR - Czech Science Foundation (CSF) CEZ AV0Z5011922 - FGU-C Annotation Several lines of evidence suggest that angiotensin converting enzyme (ACE) inhibitors and some angiotensin II receptor blockers (ARBs) may improve insulin sensitivity and decrease the risk for type 2 diabetes. Recent studies suggest that ACE inhibitors might improve glucose metabolism primarily through effects on kinin-nitric oxide pathways. In addition, one ARB in particular, telmisartan, has been found to activate the peroxisome proliferator activated receptor gamma (PPARgamma), a well known target for insulin sensitizing, antidiabetic drugs. Thus, the beneficial metabolic effects of some ACE inhibitors and ARBs may go well beyond their effects on the renin-angiotensin system Workplace Institute of Physiology Contact Lucie Trajhanová, lucie.trajhanova@fgu.cas.cz, Tel.: 241 062 400 Year of Publishing 2005
Number of the records: 1